Literature DB >> 9641506

Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus.

L J Jara1, L Irigoyen, M J Ortiz, B Zazueta, G Bravo, L R Espinoza.   

Abstract

We investigated the levels of prolactin (PRL) and interleukin-6 (IL-6) in the cerebrospinal fluid (CSF) and serum of systemic lupus erythematosus patients with central nervous system involvement (CNS-SLE), and examined whether PRL and IL-6 have a relationship. Serum and CSF PRL and IL-6 were measured in the following groups of patients and controls: group I: seven patients with CNS-SLE; group II: three SLE patients without CNS involvement (non CNS-SLE); group III: 10 patients with neurocysticercosis; and group IV: six healthy women. The patients were clinically assessed. CSF PRL and IL-6 were elevated in group I (CNS-SLE) in comparison with all other groups (p<0.001). In addition, four of seven patients had higher levels of IL-6 and PRL in CSF than in serum. A positive correlation between PRL and IL-6 in CSF of SLE was observed (r=0.88, p<0.001). The mean serum PRL concentrations were not significantly different in all groups, but high levels of IL-6 were found in the serum of group I in comparison with groups II and IV (p<0.001). The serum levels of group III were not different from those of group I. These results demonstrate the presence of intrathecal synthesis and elevations of CSF PRL and IL-6 in active CNS-SLE involvement and indicate that measurements of CSF PRL and IL-6 may be useful in the evaluation of neuropsychiatric lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9641506     DOI: 10.1007/bf01452255

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  Characterization of prolactin immunoreactivity in human cerebrospinal fluid.

Authors:  F Nyberg; C A Isacson; E Brostedt; P Roos
Journal:  Brain Res       Date:  1990-01-01       Impact factor: 3.252

2.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

3.  Prolactin in human and rat serum and cerebrospinal fluid.

Authors:  I S Login; R M MacLeod
Journal:  Brain Res       Date:  1977-09-02       Impact factor: 3.252

4.  Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement.

Authors:  S Hirohata; T Miyamoto
Journal:  Arthritis Rheum       Date:  1990-05

5.  Prolactin influences autoimmune disease activity in the female B/W mouse.

Authors:  R McMurray; D Keisler; K Kanuckel; S Izui; S E Walker
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

6.  Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus.

Authors:  L Jara-Quezada; A Graef; C Lavalle
Journal:  J Rheumatol       Date:  1991-03       Impact factor: 4.666

7.  Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers.

Authors:  J Alcocer-Varela; D Aleman-Hoey; D Alarcon-Segovia
Journal:  Lupus       Date:  1992-02       Impact factor: 2.911

8.  Characterization by enzyme-linked immunosorbent assay of the humoral immune response in patients with neurocysticercosis and its application in immunodiagnosis.

Authors:  B Espinoza; G Ruiz-Palacios; A Tovar; M A Sandoval; A Plancarte; A Flisser
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

9.  No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus.

Authors:  D Buskila; M Lorber; L Neumann; D Flusser; Y Shoenfeld
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

10.  Prolactin in systemic lupus erythematosus.

Authors:  R Pauzner; M B Urowitz; D D Gladman; J M Gough
Journal:  J Rheumatol       Date:  1994-11       Impact factor: 4.666

View more
  11 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

Review 2.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

3.  Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients.

Authors:  Hedi Orbach; Gisele Zandman-Goddard; Mona Boaz; Nancy Agmon-Levin; Howard Amital; Zoltan Szekanecz; Gabriella Szucs; Josef Rovensky; Emese Kiss; Andrea Doria; Anna Ghirardello; Jesus Gomez-Arbesu; Ljudmila Stojanovich; Francesca Ingegnoli; Pier Luigi Meroni; Blaz' Rozman; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

4.  Prolactin has a pathogenic role in systemic lupus erythematosus.

Authors:  Luis J Jara; Gabriela Medina; Miguel A Saavedra; Olga Vera-Lastra; Honorio Torres-Aguilar; Carmen Navarro; Monica Vazquez Del Mercado; Luis R Espinoza
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

5.  Behavioral heterogeneity in an animal model of neuropsychiatric lupus.

Authors:  Boris Sakic; Steven E Hanna; Jason M Millward
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

6.  HLA-DRB1 and -DQB1 alleles and gene polymorphisms of selected cytokines in systemic lupus erythematosus.

Authors:  Antoni Hrycek; Urszula Siekiera; Paweł Cieślik; Witold Szkróbka
Journal:  Rheumatol Int       Date:  2004-09-21       Impact factor: 2.631

Review 7.  Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Akiko Kobayashi; Hisashi Yamanaka
Journal:  J Biomed Biotechnol       Date:  2010-06-29

Review 8.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

9.  Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.

Authors:  V Larouche; J A Correa; P Cassidy; C Beauregard; N Garfield; J Rivera
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

10.  Effect of proinflammatory cytokines (IL-6, TNF-α, and IL-1β) on clinical manifestations in Indian SLE patients.

Authors:  Vinod Umare; Vandana Pradhan; Milind Nadkar; Anjali Rajadhyaksha; Manisha Patwardhan; Kanjaksha K Ghosh; Anita H Nadkarni
Journal:  Mediators Inflamm       Date:  2014-12-07       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.